A prospective study of mediastinal gray-zone lymphoma

Blood

Volumn 124, Issue 10, 2014, Pages 1563-1569

  Wilson, Wyndham H ^a   Pittaluga, Stefania ^a   Nicolae, Alina ^a   Camphausen, Kevin ^a   Shovlin, Margaret ^a   Steinberg, Seth M ^a   Roschewski, Mark ^a   Staudt, Louis M ^a   Jaffe, Elaine S ^a   Dunleavy, Kieron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; CANCER CELL; CANCER MORPHOLOGY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DENDRITIC CELL; DRUG FEVER; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; ILEUS; LYMPHOCYTE COUNT; LYMPHOMA; MALE; MEDIASTINAL GRAY ZONE LYMPHOMA; MEDIASTINUM TUMOR; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY MEDIASTINAL B CELL LYMPHOMA; PROSPECTIVE STUDY; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TUMOR ASSOCIATED LEUKOCYTE; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOTHERAPY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84907058311     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-564906     Document Type: Article

References (27)

1. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871-3879.
2. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
3. Swerdlow S, Harris NL, Campo E, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008.
4. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29(11):1411-1421.
5. Quintanilla-Martinez L, de Jong D, de Mascarel A, et al. Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematop. 2009;2(4):211-236.
6. Pileri S, Bocchia M, Baroni CD, et al. Anaplastic large cell lymphoma (CD30 +/Ki-1+): results of a prospective clinico-pathological study of 69 cases. Br J Haematol. 1994;86(3):513-523.
7. Grant C, Dunleavy K, Eberle FC, Pittaluga S, Wilson WH, Jaffe ES. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6(3):157-163.
8. Zinzani PL, Martelli M, Magagnoli M, et al. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood. 1998;92(3):790-794.
9. Eberle FC, Salaverria I, Steidl C, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24(12):1586-1597.
10. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-1416.
11. Wilson WH, Jung SH, Porcu P, et al; Cancer Leukemia Group B. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758-765.
12. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717-2724.
13. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
14. Juweid ME, Stroobants S, Hoekstra OS, et al; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578.
15. Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma. 2014;55(1):31-37.
16. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257-1260.
17. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
20. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
21. Dunleavy K, Nicolae A, Pittaluga S, et al. Study on the biology and treatment of mediastinal grey zone lymphoma. [abstract]. Hematol Oncol. 2013;31(S1). Abstract 75.
22. Geijtenbeek TB, Krooshoop DJ, Bleijs DA, et al. DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol. 2000;1(4):353-357.
23. Longo DL, Glatstein E, Duffey PL, et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol. 1997;15(11):3338-3346.
24. Schwering I, Bräuninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101(4):1505-1512.
25. Bradley AJ, Carrington BM, Lawrance JA, Ryder WD, Radford JA. Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. J Clin Oncol. 1999;17(8):2493-2498.
26. Evens AM, Kanakry JA, Sehn LH, et al. Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis of Clinical Characteristics, Treatment, Outcomes and Prognosis in the Current Era. ASH Annual Meeting Abstracts 2013. 122:847.
27. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.